DANIEL ARAUJO FERRAZ
Projetos de Pesquisa
Unidades Organizacionais
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
- Fundus autofluorescence imaging: Fundamentals and clinical relevance(2014) SEPAH, Y. J.; AKHTAR, A.; HAFEEZ, Y.; NASIR, H.; PEREZ, B.; MAWJI, N.; SADIQ, M. A.; DEAN, D. J.; FERRA, D. A.; NGUYEN, Q. D.Fundus autofluorescence (FAF) is a relatively new, noninvasive imaging modality that has been developed over the past decade. The autofluorescence (AF) images are obtained through the use of confocal scanning laser ophthalmoscopy (cSLO). It uses the fluorescent properties of lipofuscin (LP) to generate images that provide information beyond that is acquired by utilizing more conventional imaging methods such as fluorescein angiography, fundus photography, and regular optical coherence tomography (OCT). FAF has been an area of interest in ophthalmic research for over 40 years. However, it has only recently become clinically relevant because of various important technological advances. FAF has proved to be helpful in understanding the pathophysiological mechanisms, diagnostics, and identification of predictive markers for disease progression and for monitoring of novel therapies. © 2014 by Taylor & Francis Group, LLC.
- Short-term effects of intravitreal bevacizumab in contrast sensitivity of patients with diabetic macular edema and optimizing glycemic control(2019) MOTTA, Augusto A. L.; BONANOMI, Maria Teresa B. C.; FERRAZ, Daniel A.; PRETI, Rony C.; SOPHIE, Raafay; ABALEM, Maria F.; QUEIROZ, Marcia S.; PIMENTEL, Sergio L. G.; TAKAHASHI, Walter Y.; DAMICO, Francisco M.Aims: To analyze contrast sensitivity of intravitreal bevacizumab injections with optimizing glycemic control versus optimizing glycemic control (in combination with sham injections) in eyes with Diabetic Macular Edema (DME). Design: Prospective, interventional, masked, randomized controlled trial. Methods: Forty-one eyes of 34 patients with type 2 diabetes mellitus and DME with glycated hemoglobin (HbA1c) < 11% received either intravitreal bevacizumab injection (Group 1) or sham injection (Group 2) at 0 and 6 weeks along with optimizing glycemic control. Mean change in best-corrected visual acuity (BCVA), contrast sensitivity (CS), optical coherence tomography (OCT)-measured by central macular thickness (CMT) were compared and correlated at baseline, 2, 6 and 12 weeks. Results: The study showed a mean CS improved in group 1 from 1.14 +/- 0.36 logCS to 1.32 +/- 0.24 logCS and also in group 2 from 1.11 +/- 0.29 logCS to 1.18 +/- 0.29 logCS at 12 weeks (P = 0.12). CS and CMT promptly decreased in group 1 compared to group 2 at 2 weeks (Delta CS = 0.15 +/- 0.25 vs. 0.03 +/- 0.15 logCS; P = 0.04; Delta CMT = 116 +/- 115 vs. 17 +/- 71 mu m; P = 0.01). There was a mean reduction of approximately 0.5% in HbA1c levels in both groups at 12 weeks (P = 0.002). Conclusion: The use of bevacizumab in combination with optimizing glycemic control results in earlier improvement of contrast sensitivity in type 2 diabetes patients with DME. However, the optimizing glycemic control itself has shown also to be effective at 12 weeks.
conferenceObject Intravitreal Ranibizumab Combined with Panretinal Photocoagulation in Patients with Treatment-Naive Proliferative Diabetic Retinopathy(2013) FERRAZ, Daniel; SOPHIE, Raafay; BITTENCOURT, Millena; PRETI, Rony; VAZQUEZ, Lisa; MOTTA, Augusto; HANOUT, Mostafa; SEPAH, Yasir; Quan Dong Nguyen; TAKAHASHI, Walter- Optical coherence tomography(2014) IBRAHIM, M. A.; SEPAH, Y. J.; BITTENCOURT, M. G.; LIU, H.; HANOUTL, M.; FERRAZ, D. A.; DO, D. V.; NGUYEN, Q. D.Optical coherence tomography (OCT) is widely used in imaging of biological tissues such as eye, skin, and most recently blood vessels. In this chapter, we will give a brief history of OCT and its development, especially during the most recent years. We will also discuss about the physical principles underlying the technology. The spectrum of OCT applications is expanding quickly to include new medical and industrial disciplines. However, in this chapter, we will focus on the applications of OCT in the ophthalmological field, more specifically, in retina. Lastly, we will briefly discuss newer developments in OCT technologies with focus on research topics and future directions of use in ocular diseases. © 2014 by Taylor & Francis Group, LLC.
- Scanning laser ophthalmoscope fundus perimetry: The microperimetry(2014) BITTENCOURT, M. G.; FERRAZ, D. A.; LIU, H.; HANOUT, M.; SEPAH, Y. J.; DO, D. V.; NGUYEN, Q. D.Visual perception is the ultimate outcome of a variety of discriminative functions of the visual system in which the macular function plays a great role. For many years, physicians relied on best-corrected visual acuity (VA) measurements and retinoscopy to assess macular dysfunction. It is well known, however, that VA cannot fully distinguish deterioration of macular function. Throughout the ophthalmic history, several clinical examinations were designed to aid in the assessment of the various aspects of the visual function. Some of them are still in use such as contrast sensitivity, reading speed, macular recovery function, low-luminance VA, and color acuity, among others. However, no other functional test has shown the same ability of localizing retinal function depression as perimetry does. © 2014 by Taylor & Francis Group, LLC.
conferenceObject Infra-red photography retinal abnormalities and inner nuclear layer microcystic retinal degeneration in eyes with band atrophy of the optic nerve(2014) MONTEIRO, Mario L. R.; SOUSA, Rafael Miranda Miranda; FERRAZ, Daniel Araujo; RAJAGOPALAN, Nithya; SADIQ, Mohammad Ali; SEPAH, Yasir; Quan Dong Nguyen; TAKAHASHI, Walter Y.article 39 Citação(ões) na Scopus A RANDOMIZED CONTROLLED TRIAL OF PANRETINAL PHOTOCOAGULATION WITH AND WITHOUT INTRAVITREAL RANIBIZUMAB IN TREATMENT-NAIVE EYES WITH NON-HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY(2015) FERRAZ, Daniel A.; VASQUEZ, Lisa M.; PRETI, Rony C.; MOTTA, Augusto; SOPHIE, Raafay; BITTENCOURT, Millena G.; SEPAH, Yasir J.; MONTEIRO, Mario L. R.; Quan Dong Nguyen; TAKAHASHI, Walter YukihikoPurpose: To compare the efficacy of panretinal photocoagulation (PRP) and intravitreal ranibizumab injection with PRP alone in patients with treatment-naive bilateral non-high-risk proliferative diabetic retinopathy. Methods: Sixty eyes of 30 patients were randomized either to the study group (SG) receiving PRP plus 2 ranibizumab injections or to the control group (CG) receiving PRP alone. Mean change in best-corrected visual acuity and in optical coherence tomography were compared at baseline and 1, 3, and 6 months. Results: Best-corrected visual acuity was significantly better at 6 months in the SG; however, there was decrease in best-corrected visual acuity in the CG. Central macula thickness decreased significantly at 6 months in SG when compared with baseline (-47.6 mm, P < 0.001) and did not reveal significant difference in the CG. In eyes with diabetic macular edema, best-corrected visual acuity increased by 3.6 letters (P = 0.06) in the SG and decreased by 4.4 letters in the CG (P = 0.003). Central macula thickness decreased by 69.3 mm (P = 0.001) in the SG and decreased by 45.5 mm (P = 0.11) in the CG. Conclusion: Intravitreal ranibizumab in combination with PRP can be an effective treatment in eyes with non-high-risk proliferative diabetic retinopathy and diabetic macular edema.conferenceObject Contrast sensitivity evaluation in high-risk treatment-naive proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal Ranibizumab.(2014) FERRAZ, Daniel Araujo; VASQUEZ, Lisa; MOTTA, Augusto; PRETI, Rony C.; SOPHIE, Raafay; BITTENCOURT, Millena Gomes; MONTEIRO, Mario L. R.; TAKAHASHI, Walter Y.- Therapies for Neovascular Age-Related Macular Degeneration: Current Approaches and Pharmacologic Agents in Development(2013) HANOUT, Mostafa; FERRAZ, Daniel; ANSARI, Mehreen; MAQSOOD, Natasha; KHERANI, Saleema; SEPAH, Yasir J.; RAJAGOPALAN, Nithya; IBRAHIM, Mohamed; DO, Diana V.; Quan Dong NguyenAs one of the leading causes of blindness, age-related macular degeneration (AMD) has remained at the epicenter of clinical research in ophthalmology. During the past decade, focus of researchers has ranged from understanding the role of vascular endothelial growth factor (VEGF) in the angiogenic cascades to developing new therapies for retinal vascular diseases. Anti-VEGF agents such as ranibizumab and aflibercept are becoming increasingly well-established therapies and have replaced earlier approaches such as laser photocoagulation or photodynamic therapy. Many other new therapeutic agents, which are in the early phase clinical trials, have shown promising results. The purpose of this paper is to briefly review the available treatment modalities for neovascular AMD and then focus on promising new therapies that are currently in various stages of development.